|Bid||1.2700 x 1200|
|Ask||1.2800 x 800|
|Day's Range||1.2000 - 1.3700|
|52 Week Range||0.6100 - 1.9200|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 25, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology today reports its 2019 financial results and provides a business update.
Pulmatrix, Inc. (NASDAQ: PULM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PUR1900 ("Pulmazole"), the Company's inhaled itraconazole antifungal candidate being developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. Pulmatrix is currently enrolling patients in its ongoing randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety, tolerability, pulmonary function and biomarker response of Pulmazole in subjects with asthma-ABPA. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier.
Pulmatrix, Inc. (NASDAQ: PULM) announced today that it received a letter from the listing qualifications department staff of The Nasdaq Stock Market LLC, stating that the Company has regained compliance with Nasdaq's minimum $1.00 per share bid price requirement.
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced that it has entered into a research collaboration with Nocion Therapeutics to explore new technologies to enable and improve inhaled drug delivery. The collaboration will leverage Pulmatrix's iSPERSE™ platform and expertise in seeking to transform promising assets to improve drug delivery and safety profiles.
Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson*. Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors intended for development in lung cancer interception.
LEXINGTON, Mass., Nov. 4, 2019 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced the appointment of Rick Batycky, Ph.D., to its Board of Directors. "Rick brings deep expertise in drug development to the board and we are thrilled to welcome him," said Ted Raad, Chief Executive Officer of Pulmatrix. "His broad ranging experience in respiratory therapeutics, including Pulmatrix's iSPERSE™ dry powder inhalation technology will be invaluable as we consider opportunities to bring new therapeutics to market.
LEXINGTON, Mass. , Nov. 1, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today reports its third quarter results. Q3 2019 Highlights Pulmatrix achieved clinical and business milestones which reflect ...
Phase 2 clinical trial initiated and enrollment progressing across 24 sites Study to support proof-of-concept mechanism with top line data expected mid-2020 LEXINGTON, Mass. , Sept. 18, 2019 /PRNewswire/ ...
LEXINGTON, Mass., Aug. 19, 2019 /PRNewswire/ -- Pulmatrix, Inc. (PULM) has received a grant from the United States Patent and Trademark Office for US Pat. No. 10376465. Granted claims cover iSPERSE formulations of the company's lead pipeline program Pulmazole. The patent, entitled "Monovalent Metal Cation Dry Powders for Inhalation", protects formulations that contain an anti-fungal agent with iSPERSE formulations. iSPERSE is Pulmatrix's proprietary inhaled engineered particle technology. "The expansion of our iSPERSE intellectual property rights in the United States builds upon our growing worldwide patent estate supporting our platform technology and our proprietary programs. This patent is a valuable step in supporting the development of our lead anti-fungal program to serve unmet needs of patients worldwide," said Ted Raad, chief executive officer of Pulmatrix.
LEXINGTON, Mass. , Aug. 5, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. Q2 2019 Highlights Pulmatrix achieved several clinical and business milestones ...
LEXINGTON, Mass., May 16, 2019 /PRNewswire/ -- Pulmatrix, Inc. (PULM) announces today that Dr. Robert Clarke has stepped down as Chief Executive Officer. Ted Raad will immediately transition from his current role as Chief Business Officer to that of Chief Executive Officer and member of the Pulmatrix Board of Directors. In order to ensure a smooth transition, Dr. Clarke will continue as an advisor to the Board of Directors and Company Management through August 14, 2019.
LEXINGTON, Mass. , May 15, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone in the first quarter with the FDA providing approval ...
- Transaction marks Cipla's entry into specialty respiratory segment, building on inroads made into the specialty business in the recent past - iSPERSE™ formulation of the anti-fungal drug itraconazole ...
LEXINGTON, Mass., April 8, 2019 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (PULM) today announced the closing of its previously announced underwritten public offering of an aggregate of 1,719,554 common units and 8,947,112 pre-funded units at a price to the public of $1.35 per common unit and $1.34 per pre-funded unit, as well as the purchase of an additional 1,599,999 shares of common stock and common warrants to purchase an additional 1,599,999 shares of common stock purchased pursuant to the exercise in full of the underwriter's option to purchase additional securities. Each common unit contains one share of common stock (or, in the case of the pre-funded units, one pre-funded warrant) and one common warrant to purchase a share of common stock.